HCPCS code J9352: Trabectedin injection, per 0.1 mg2026 Medicare rate & RVUs in Michigan
J9352 identifies trabectedin in 0.1 mg units, but Medicare uses J9362 for current reporting, with a 0.01 mg unit basis.
CMS doesn’t publish an office rate for J9352 in Michigan.
Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.
Your location
On this page 9 sections
What J9352 covers
Trabectedin is an antineoplastic drug given by intravenous infusion, typically in oncology settings for patients with unresectable or metastatic liposarcoma or leiomyosarcoma. Oncology practices report the drug for the amount administered; J9352's unit basis is 0.1 mg per unit. Trabectedin infusions commonly involve a prolonged infusion, with dexamethasone given beforehand as premedication.
J9352 has Medicare physician fee schedule status I: it is not valid for Medicare, which uses J9362 to report trabectedin instead. The HCPCS pricing method identifies it as a Part B drug, generally priced through CMS quarterly Average Sales Price files when covered; that pricing method does not make J9352 valid for Medicare billing. Coverage is left to the Medicare contractor's judgment. For Medicare claims, use J9362 and its 0.01 mg unit basis rather than converting the administered dose into J9352 units.
This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.
Where J9352 pays more and less in Michigan
| Payment locality | Office | Facility |
|---|---|---|
| Detroit, MI | Unavailable | Unavailable |
| Rest of Michigan | Unavailable | Unavailable |
How the J9352 rate is calculated
Each of J9352’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.
How the rate is built · J9352
RVUs × geographic indexes × conversion factor
Work0.00
0.00 RVUs× 1.000 GPCI
Practice expense0.00
0.00 RVUs× 1.000 GPCI
Malpractice0.00
0.00 RVUs× 1.000 GPCI
Adjusted RVUs
0.0000
Conversion factor
$33.4009
Medicare rate
$0.00
Every GPCI starts at 1.000, the national rate. Enter a ZIP or drag a slider.
Payment rules and modifiers for J9352
J9352 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.
Place of service · J9352
Which rate does Medicare pay?
The POS code on the claim line (CMS-1500 box 24B).
POS 11 · non-facility rate · national
—
J9352 isn’t priced in this setting.
J9352 compared with similar codes
Compare codes · National
4 codes, side by side
How to choose
- J9362Trabectedin injectionPer 0.01 mg
- Both identify trabectedin, but Medicare uses J9362, which measures the drug in 0.01 mg units. J9352 is not valid for Medicare.
- J9351Topotecan injectionPer 0.1 mg
- J9351 identifies topotecan, a different antineoplastic drug. It is not an alternative code for trabectedin.
- J9354Ado-trastuzumab emtansinePer 1 mg
- J9354 identifies ado-trastuzumab emtansine, not trabectedin. Choose by the drug administered, not by the shared oncology-drug code range.
J9352 billing questions
Which code should Medicare claims use for trabectedin?
Use J9362, which reports trabectedin in 0.01 mg units. J9352 is not valid for Medicare.
What did one J9352 unit represent?
One unit represented 0.1 mg of trabectedin. J9352 is not valid for Medicare reporting.
Can a modifier make J9352 payable by Medicare?
No. J9352 has Medicare status I and is not valid for Medicare; use J9362 for trabectedin.
Is trabectedin reported with its infusion administration?
The drug and its administration are distinct services. A prolonged chemotherapy infusion may be reported with CPT 96416 when the service meets that code's requirements.
How does Medicare determine coverage for trabectedin?
Coverage is left to the Medicare contractor's judgment. The HCPCS pricing method identifies trabectedin as a Part B drug generally priced through CMS quarterly ASP files when covered.
Where these rates come from
FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.
CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027
Fee sheets · Coming soon
Put J9352 and the rest of your codes on one sheet
Your codes at your locality, with payer contracts beside Medicare.
Join the waitlist